Ignite Creation Date:
2024-05-05 @ 11:34 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00087997
Status:
COMPLETED
Last Update Posted:
2006-06-20
First Post:
2004-07-19
Brief Title:
A Study of STA-4783 in Combination With Weekly Paclitaxel for Treatment of Patients With Soft Tissue Sarcomas
Sponsor:
Synta Pharmaceuticals Corp
Organization:
Synta Pharmaceuticals Corp
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2006-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety and effectiveness of an experimental study drug STA-4783 combined with an approved cancer medicine paclitaxel in the treatment of soft tissue sarcomas Paclitaxel Taxol has been approved and used in the United States since 1992
Detailed Description:
STA-4783 is a taxane potentiator enhancing the effect of antitumor response of paclitaxel In an attempt to improve efficacy paclitaxel is sometimes used in combination with other anticancer agents When paclitaxel is combined with other anticancer agents although response rate is usually increased side effects are usually increased as well There is an urgent need for agents that can enhance the antitumor effects of paclitaxel without further increasing undesirable side effects
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None